Click on the tabs above by lung cancer type to view active trials.
| Protocol # | Sponsor | Protocol Title |
|---|---|---|
| NCT02296125 | AstraZeneca D5160C00007, 2014-002694-11, U1111-1160-2242 | A Phase III, Double-blind, Randomized Study to Assess the Safety and Efficacy of AZD9291 Versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non Small Cell Lung Cancer |
| NCT02367781 | Hoffmann-La Roche GO29537, 2014-003206-32 | A Phase III Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel for Chemotherapy-Naive Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer |
| NCT02367794 | Hoffmann-La Roche GO29437 | A Phase III, Open-label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of MPDL3208A (Anti-PDL-1 Antibody) in Combination with Carboplatin + Paclitaxel or MPDL3208A in Combination with Carboplatin + Nab-paclitaxel Versus Carboplatin + Nab-paclitaxel in Chemotherapy-naive Patients with Stage IV Squamous Non-small Cell Lung Cancer |
| NCT02125461 | AstraZeneca D4191C00001 | A Phase III Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients with Stage III Unresectable Non-Small Cell Lung Cancer |
| NCT02477826 | Bristol-Myers Squibb CA209-227, 2014-003630-23 | An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, Versus Platinum Doublet Chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) |
Pemetrexed in combination with platin-chemotherapy has been demonstrated to be superior to gemcitabine-platin chemotherapy in non-squamous NSCLC. Anti-angiogenic therapy with bevacizumab has demonstrated survival benefit when added to paclitaxel-carboplatin chemotherapy in non-squamous NSCLC. Small molecule inhibitors of the Epidermal Growth Factor Receptor (EGFR) have been demonstrated to improve survival in patients with NSCLC previously treated with chemotherapy, and have even been established as superior to chemotherapy in first-line treatment of NSCLC harboring activating mutations of EGFR.
NGOC cancer doctors are offering participation in several clinical trials evaluating these agents and pathways. We are increasingly able to offer individualized, personalized approaches based on individual tumor characteristics.
| Protocol # | Sponsor | Protocol Title |
|---|---|---|
| NCT0220757 | CytRx | A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Refractory to Prior Chemotherapy |
Pemetrexed in combination with platin-chemotherapy has been demonstrated to be superior to gemcitabine-platin chemotherapy in non-squamous NSCLC. Anti-angiogenic therapy with bevacizumab has demonstrated survival benefit when added to paclitaxel-carboplatin chemotherapy in non-squamous NSCLC. Small molecule inhibitors of the Epidermal Growth Factor Receptor (EGFR) have been demonstrated to improve survival in patients with NSCLC previously treated with chemotherapy, and have even been established as superior to chemotherapy in first-line treatment of NSCLC harboring activating mutations of EGFR.
NGOC cancer doctors are offering participation in several clinical trials evaluating these agents and pathways. We are increasingly able to offer individualized, personalized approaches based on individual tumor characteristics.